---
title: "Policy Pulse — Trump / US Watch — 20 Oct 2026"
ticker: "JPM:GS:DHI:LEN:PHM:MSFT:GOOGL:ORCL:PLTR:NVDA:GD:TXT:NOC:RTX:GE:LMT:HII:MP:USAR:AREC:HOLX:OGN:PFE:ABBV:TMO:MMM:EFX:GM:STLD:CRWV:META"
date: "2026-10-20"
tags: ["policy-pulse","us-only","fed","ai-policy","tariffs","defence"]
summary: "Ninety-four of 100 economists now expect the Fed to hold on Oct 27-28 and all 100 expect a December hike, which keeps a floor under JPM and GS while extending the pain for DHI, LEN and PHM; separately DHS ordered DeepSeek out of civilian agency IT, a procurement positive for MSFT and ORCL."
model: "deepseek-v4-flash"
---

## The October Skip Is Now Consensus, and December Is the Live Meeting

The most useful number published today was not a market print. It was a poll.

Reuters surveyed 100 economists between **October 16 and 20**, and **94 of them expect the FOMC to hold the federal funds rate at 3.75%-4.00%** when it meets on **October 27-28** — the meeting that lands six days before the midterms. That part is priced. The part that is not fully priced is the second line: **all 100 respondents now expect a rate hike in December**, against fewer than half saying so in last month's poll. **Roughly 60% see the peak at 4.00%-4.25%**, but **38 of 92 forecasters expect at least two further increases**, up from one-fifth in September.

The inflation arithmetic behind that shift is unforgiving. The poll's median has the Fed's preferred **PCE gauge more than 100 basis points above the 2% target over coming quarters and not back to target until at least 2028**. Inflation has now been above target for nearly six years. Third-quarter GDP is forecast at **3.2%**, slowing to 2.2% in October-December, with annual growth of 2.3% this year and 2.1% in 2027 — above the 2.0% the Fed considers non-inflationary.

Chair **Kevin Warsh** has given no guidance, and the recent messaging has whipsawed the curve: long-dated Treasury yields hit multi-decade highs on **October 7** on inflation and near-term hike expectations, then retreated nearly **25 basis points** as October hike odds collapsed.

Two quotes capture the split. **Alex Pelle of Mizuho**: "Them not going in October is the wrong call from a policy point of view. They'll go 25 in December, but the risk is greater they end up going 50 than they don't go at all." **Michael Gapen of Morgan Stanley**: "The risks are in the direction of a Fed that ultimately needs to hike rates more than we expect."

The political overlay matters for how tariffs get handled between now and November 3. Inflation has been driven by energy costs from the Iran conflict and by tariffs on imported goods, and that combination is the Republicans' weakest issue in an election being fought on affordability.

The transmission is already visible in housing, and today's data was bad. **US single-family housing starts plunged in September and building permits hit a 3-1/2-year low**; separately, **pending home sales tumbled to a record low** for the month. A 30-year mortgage priced off a 5%-plus 10-year Treasury does that.

| Stock | Impact | Reason | Confidence |
|---|---|---|---|
| JPM, GS | 🟢 Positive | ⚠️ inferred. A hold-plus-December-hike path keeps net interest margins elevated for longer than a cut cycle would; financials were up about 1% today and led with healthcare | 3/5 |
| DHI, LEN, PHM | 🔴 Negative | ⚠️ inferred. Permits at a 3-1/2-year low and record-low pending sales are the demand side of the same rate story; a December hike removes the "relief rally" case for the group | 3/5 |

## Homeland Security Orders DeepSeek Out of Civilian Agency IT

The **Department of Homeland Security** published a notice on the Federal Register on Monday ordering the removal of **DeepSeek** products, and of third-party services built using DeepSeek models, from **US civilian executive-branch agency IT systems**. It also bars those agencies from **acquiring** such products going forward. Department of Defense components are excluded from the order.

The rationale in the attached document is that DeepSeek's models "present multiple threat vectors" and that use by government employees or vendors "may result in the transfer of sensitive data" to China, whose legal system gives the government extensive authority over company infrastructure. Commerce and the Navy had already banned DeepSeek on government devices; this is the first civilian-wide removal-and-procurement order.

Beijing answered within a day. China's commerce ministry said on Tuesday that the order **"disregards important consensus" reached between Xi Jinping and Trump, "seriously hurts Chinese firms' interests"** and interferes with normal commercial cooperation, and urged Washington to "immediately correct wrong practices... and revoke relevant discriminatory restrictions."

This is the second concrete AI-decoupling act in a fortnight, and it lands with the **January 10, 2027** tariff-truce expiry ahead and a leaders' summit in Shenzhen expected next month. The practical read for equities is narrower than the headlines: it is a procurement signal, not a demand signal.

| Stock | Impact | Reason | Confidence |
|---|---|---|---|
| MSFT, GOOGL | 🟢 Positive | ⚠️ inferred. Excluding a low-cost Chinese model from federal workflows pushes agencies back onto US-hosted frontier and enterprise stacks, which is where Azure/OpenAI and Google Cloud sit | 3/5 |
| ORCL, PLTR | 🟢 Positive | ⚠️ inferred. Both sell accredited government cloud and analytics; a removal-and-replacement mandate is incremental contract volume in a segment they already dominate | 3/5 |
| NVDA | 🟡 Watch | ⚠️ inferred. The ban does not change training demand, and Chinese open-weight models were never run on federal GPUs; the read-across is sentiment, not units | 2/5 |

## Trump Eases Off Bombardier in Wichita

At a rally in Park City, Kansas on Monday night for Senator **Roger Marshall**, Trump walked back his September threat to bar **Bombardier** from the US market: "I'm going to be helping a certain air company get themselves straightened away... But now I find out they have a presence here, and we're not hurting them if they're in Kansas. So we'll take care of those people and the jobs."

The company employs **3,500 people in the US, more than 40% of them in Wichita**, which hosts Bombardier Group's US headquarters and Bombardier Defense; it announced a further **$50 million** Wichita investment last week. **Bombardier shares rose 2.1%** on Tuesday.

The context is the Canada file, which is the most legally fragile part of the tariff programme. Washington imposed duties on about **$20 billion of Canadian goods in August**, Canada retaliated in early September, and the US banned a broad swath of **Canadian alcoholic beverages, motorcycles and dairy products** from **September 29** — but took no action against Bombardier. The February threat to decertify Bombardier jets over a certification spat involving **Gulfstream** never materialised either.

| Stock | Impact | Reason | Confidence |
|---|---|---|---|
| GD | 🟡 Watch | ⚠️ inferred. Gulfstream was the named beneficiary of the certification dispute; a White House that has decided not to squeeze Bombardier has less reason to keep leaning on the FAA/Transport Canada standoff | 2/5 |
| TXT | 🟡 Watch | ⚠️ inferred. Textron's Cessna and Beechcraft lines compete directly in light and mid-size jets, so a Bombardier reprieve is a competitive negative that is smaller than the relief in business-jet sentiment | 2/5 |

## Defence Primes Raise Guidance on Record Backlogs

Three of the largest US aerospace and defence names reported and two of them raised full-year guidance on Tuesday.

- **Northrop Grumman** lifted 2026 adjusted EPS to **$29.35-$29.75** from $28.60-$29.10. Aeronautics Systems sales rose **14%** on higher B-21 and F-35 work; the company booked **$16.4 billion** of net awards in the quarter, a book-to-bill of **1.5x**, and backlog reached a record **$109.6 billion**. Shares rose **7.2%** early.
- **RTX** raised adjusted EPS to **$7.65-$7.75** from $7.10-$7.25 and sales to **$97-97.5 billion** from $95-96 billion. Raytheon sales rose **14%** on Patriot, Standard Missile and Tomahawk volume, and total backlog hit a record **$340 billion, up 36% year on year**, on $81 billion of new commercial and defence awards. Shares gained **2.4%**.
- **GE Aerospace** raised EPS to **$8.00-$8.10** from $7.65-$7.85, with commercial engines and services revenue up more than a fifth to **$10.34 billion** — but the stock fell **4.9%** on weaker-than-expected implied fourth-quarter earnings, and management warned that prolonged high fuel prices could push airlines to cut flying.

That last caveat is the honest one in the group: defence backlogs are funded by geopolitical tension, but aftermarket revenue is funded by airlines that are currently paying more than $100 for Brent.

| Stock | Impact | Reason | Confidence |
|---|---|---|---|
| NOC | 🟢 Positive | ✅ named. Guidance raise plus record backlog plus a 1.5x book-to-bill is the cleanest read in the sector | 4/5 |
| RTX | 🟢 Positive | ✅ named. A 36% backlog increase with missile-defence volume is the segment most directly levered to the Iran conflict | 3/5 |
| GE | 🟡 Watch | ✅ named. The raise is real but the fourth-quarter implied guide and the fuel-price warning are why the stock fell | 2/5 |
| LMT, HII | 🟡 Watch | ⚠️ inferred. Read-across on programme funding (F-35, Virginia-class) rather than company-specific news | 2/5 |

## A Rare-Earth Plant in Rochester, and the November 10 Clock

New York Governor **Kathy Hochul** announced Tuesday that **Phoenix Tailings** will build a **$375 million**, 500,000-square-foot rare-earth processing facility at Rochester's Eastman Business Park, processing about **18,000 tons** of rare-earth material a year, with partial operations next year and full production in **2028**. The state is providing **$3 million** in performance-based tax credits. The Pentagon had already conditionally committed **$500 million** in long-term debt financing to the company for a US midstream plant.

The strategic point is timing. Most US rare-earth capacity does not come online until 2027 or later, and **China's export-control pause expires on November 10** — six weeks before the US-China truce deadline of **January 10, 2027**. Every plant announced in this window is a hedge against a date, not a response to a price.

Note the listed exposure is thin and early-stage: the plant is privately held, so the trade is in the processors and miners that re-rate on each announcement rather than in the project itself.

| Stock | Impact | Reason | Confidence |
|---|---|---|---|
| MP | 🟢 Positive | ⚠️ inferred. Each new US midstream announcement validates the domestic supply-chain premium that MP's multiples already embed; it is the revenue-generating comparison | 3/5 |
| USAR, AREC | 🟡 Watch | ⚠️ inferred. Pre-revenue developers re-rate on policy headlines and give it back when the next plant is announced instead of them; treat the move as sentiment | 2/5 |

## Women's Health Gets a Division at the NIH

Trump signed an executive order on Monday creating a **women's health division inside the National Institutes of Health** and a **White House Women's Health Task Force** chaired by chief of staff **Susie Wiles** and HHS Secretary **Robert F. Kennedy Jr.** The stated priorities are maternal health, mental health and **endometriosis**; the first lady framed it around five objectives and the White House said the intent is to move beyond research funding into translating findings into clinical care.

This is a small-money order with a long-duration signal: NIH structure changes determine which conditions get trial funding, and trial funding determines which labels get expanded.

| Stock | Impact | Reason | Confidence |
|---|---|---|---|
| HOLX | 🟢 Positive | ⚠️ inferred. Women's health is the core franchise — breast imaging, cervical screening, diagnostics — and a dedicated NIH division is the funding channel for exactly that | 3/5 |
| OGN | 🟢 Positive | ⚠️ inferred. The purest listed women's-health pharma asset, with contraception and fertility exposure that a maternal-health focus touches directly | 2/5 |
| PFE, ABBV | 🟡 Watch | ⚠️ inferred. Endometriosis and maternal-health pipelines sit inside both, but at a scale where a research division is not an earnings event | 2/5 |
| TMO | 🟡 Watch | ⚠️ inferred. Trial starts are instrument and reagent orders; the effect is a two-to-three-year tail, not a quarter | 1/5 |

## The Tape: Healthcare at a Record, Energy the Laggard

At **10:31 am ET** the **Dow was 52,599.29, up 617.62 points or 1.22%**, the **S&P 500 7,744.72, up 0.70%**, and the **Nasdaq Composite 26,585.47, up 0.59%**. The session extends Monday's rebound, when the S&P 500 closed **up 0.41%** and the Nasdaq 100 **up 1.17%** while the Dow slipped 0.07% — a buy-the-dip in technology after last week's AI-financing scare.

Breadth was strong: advancers led decliners **3.55-to-1 on the NYSE** and 3.45-to-1 on the Nasdaq, the S&P posted **21 new 52-week highs against one new low**, but the Nasdaq still recorded **183 new lows** against 26 highs — the dispersion inside this market is the story, not the index level.

Sector leadership inverted the recent pattern. **Healthcare rose 1.8% to a record** and financials 1%, while **energy led the losses** as Brent reversed a move toward a near five-month high to trade **1.3% lower**; **Meta fell about 2%** and dragged communication services down.

Single names did the rest:

- **3M gained 5.3%** after expanding its data-centre partnership with **Amazon** — including a warrant for an Amazon subsidiary to buy more than **$521 million** of 3M stock — and raising its full-year profit forecast.
- **Equifax jumped 9.6%** on a third-quarter beat.
- **General Motors fell 5.3%** after guiding full-year earnings below consensus even as core profit rose 22% on pickups.
- **Steel Dynamics fell 1%** on a third-quarter miss.
- **CoreWeave rose 1.6%** and the Philadelphia Semiconductor index **0.4%** — stabilisation, not recovery.

| Stock | Impact | Reason | Confidence |
|---|---|---|---|
| MMM | 🟢 Positive | ✅ named. The Amazon data-centre tie-up plus the warrant plus a raised forecast is a re-rating catalyst for a conglomerate the market had written off | 3/5 |
| EFX | 🟢 Positive | ✅ named. A clean beat in a credit-data business is a read on consumer credit health, not on rates | 2/5 |
| GM | 🔴 Negative | ✅ named. Guidance below consensus at a 5%-plus 10-year yield and with Section 232 metals costs unresolved | 3/5 |
| STLD | 🔴 Negative | ✅ named. A third-quarter miss in steel is the tariff paradox: protection supports price, but demand is what determines volume | 2/5 |
| META | 🔴 Negative | ✅ named. A 2% decline with earnings due Wednesday is position-squaring, not a policy call | 2/5 |
| CRWV | 🟡 Watch | ✅ named. Last week's selloff was about its debt load and the cost of financing AI buildout; a 1.6% bounce does not answer that | 2/5 |

## What to Watch

- **Tonight** — SpaceX (SPCX) and Netflix report after the close; **Meta and Tesla on Wednesday**. AI-financing language in the SpaceX filing is the single highest-signal item of the week for the semis complex.
- **October 22** — the CBP de minimis compliance date for partner-government-agency data and Chapter 98/99 consignments.
- **October 26** — final US anti-dumping and countervailing duty orders on crystalline silicon solar cells from India, Indonesia and Laos (preliminary Indian margin **123.04%**).
- **October 27-28** — FOMC. **94 of 100** economists expect a hold at 3.75%-4.00%.
- **November 3** — midterms. Every tariff and sanctions decision in this window is being made against an affordability election.
- **November 10** — China's rare-earth export-control pause expires.
- **December** — every respondent in today's Reuters poll expects a hike; the debate is whether the peak is 4.00%-4.25% or higher.
- **Roughly December 15** — end of Rubio's 60-day review of the waived Graham Act duties; Sections 112 and 113 remain one determination away from coming back.